Tocqueville Asset Management’s Vaxcyte PCVX Stock Holding History

Tocqueville Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-4,200	Closed	-$244K	–	569
2026 Q1	$244K	Buy	+4,200	New	+$228K	﹤0.01%	507

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Tocqueville Asset Management's PCVX Position: Q2 2026 in Review

Tocqueville Asset Management sold out of Vaxcyte (PCVX) in Q2 2026, closing a stake of 4,200 shares — an estimated $244K sold.

Tocqueville Asset Management first reported a position in PCVX in Q1 2026 and held it in 1 quarter. The position peaked at $244K in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

Tocqueville Asset Management reported no remaining Vaxcyte position as of Q2 2026 after selling out during the quarter.
Tocqueville Asset Management sold 4,200 Vaxcyte shares in Q2 2026, an estimated $244K.
Tocqueville Asset Management first reported a position in Vaxcyte in Q1 2026 and held it in 1 quarter.
Tocqueville Asset Management's Vaxcyte position peaked at $244K in Q1 2026.
331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.